Veronate
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nosocomial Infections
Conditions
Nosocomial Infections, Sepsis, Staphylococcal Infections, Candidemia
Trial Timeline
May 1, 2004 → Jun 1, 2006
NCT ID
NCT00113191About Veronate
Veronate is a pre-clinical stage product being developed by Bristol Myers Squibb for Nosocomial Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00113191. Target conditions include Nosocomial Infections, Sepsis, Staphylococcal Infections.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00113191 | Pre-clinical | Completed |
Competing Products
7 competing products in Nosocomial Infections
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| levofloxacin; imipenem/cilastitin | Johnson & Johnson | Phase 3 | 77 |
| Ceftazidime-avibactam | AbbVie | Phase 1 | 33 |
| Ceftolozane/Tazobactam | Merck | Phase 1 | 33 |
| vancomycin monotherapy + daptomycin monotherapy | Novartis | Phase 3 | 77 |
| linezolid | Pfizer | Phase 3 | 76 |
| C Group + E Group | Pfizer | Phase 2/3 | 64 |
| ceftazidim-avibactam (CAZ-AVI, experimental product) + meropenem (active comparator) | Pfizer | Phase 3 | 76 |